Candel Therapeutics, Inc.
CADL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $195 | $242 | $245 | $245 |
| Gross Profit | -$195 | -$242 | -$245 | -$245 |
| % Margin | – | – | – | – |
| R&D Expenses | $8,266 | $6,991 | $4,016 | $4,572 |
| G&A Expenses | $0 | $4,186 | $4,114 | $0 |
| SG&A Expenses | $4,746 | $4,186 | $4,114 | $3,324 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$242 | -$245 | $0 |
| Operating Expenses | $13,012 | $10,935 | $7,885 | $7,896 |
| Operating Income | -$13,207 | -$11,177 | -$8,130 | -$8,141 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1,938 | $6,381 | $15,509 | -$5,932 |
| Pre-Tax Income | -$11,269 | -$4,796 | $7,379 | -$14,073 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$11,269 | -$4,796 | $7,379 | -$14,073 |
| % Margin | – | – | – | – |
| EPS | -0.205 | -0.093 | 0.23 | -0.4 |
| % Growth | -120.5% | -140.5% | 157.5% | – |
| EPS Diluted | -0.205 | -0.093 | 0.23 | -0.4 |
| Weighted Avg Shares Out | 54,894 | 51,490 | 31,675 | 35,565 |
| Weighted Avg Shares Out Dil | 54,894 | 51,490 | 31,675 | 35,565 |
| Supplemental Information | – | – | – | – |
| Interest Income | $953 | $926 | $934 | $290 |
| Interest Expense | $161 | $236 | $306 | $390 |
| Depreciation & Amortization | $195 | $242 | $245 | $245 |
| EBITDA | -$10,913 | -$4,318 | $7,930 | -$13,438 |
| % Margin | – | – | – | – |